^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
LabCorp

i
Other names: Omniseq | Omniseq Corporation | Personal Genome Diagnostics | Personal Genome Diagnostics Inc | Personal Genome Diagnostics, Inc. | Personal Genome Diagnostics Inc. | PGDx | Monogram Biosciences | LabCorp | Laboratory Corporation of America Holding | Laboratory Corporation of America Holdings | Monogram Biosciences, Inc. | Monogram Biosciences Inc. | Monogram Biosciences Inc | ViroLogic | ViroLogic Inc. | ViroLogic Inc
Related tests:
Evidence

News

11d
Labcorp announces expansion of precision oncology portfolio to support pharmaceutical, biopharma, and clinical research in advancing drug development programs (LabCorp Press Release)
"Labcorp...announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market."
Clinical
16d
Labcorp launches Labcorp® Plasma Detect™ extending leadership into molecular residual disease (MRD) clinical research (LabCorp Press Release)
"Labcorp...announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance."
Launch
17d
Labcorp to present diverse portfolio of precision oncology research at the Annual Meeting of the American Association for Cancer Research (LabCorp Press Release)
"Labcorp...will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research® (AACR®) in San Diego (April 5-10, 2024)...Of the 21 abstracts to be presented at the AACR Meeting, 13 were internal studies by Labcorp researchers and eight were conducted in collaboration with research partners from premiere academic institutions and medical centers."
Clinical data
1m
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer (PRNewswire)
P=NA |N=1,093 | "Consistent with prior prospective clinical trials, researchers reported that the median TTD of first-line PARP inhibitor maintenance therapy was the longest for patients with germline or somatic BRCA mutations or HRD tumors. Among the study groups, 77% of the patients with a germline BRCA mutation, 65.1% of patients with a somatic BRCA mutation, and 42.7% of those with HRD and BRCA wild-type continued PARP inhibitor therapy at 18 months, compared to 29% of patients in the HRP/BRCA wild-type group."
Real-world evidence
9ms
Labcorp forges strategic partnership with Tufts Medicine, will acquire outreach laboratory business (PRNewswire)
"Labcorp...announced an agreement with Tufts Medicine...for Labcorp to acquire the Tufts Medicine outreach laboratory business and select operating assets as a first step toward a larger strategic partnership...The arrangement will provide patients and clinicians access to Labcorp's scientific expertise and advanced diagnostics in areas such as oncology, neurology and women's health."
Licensing / partnership
11ms
Labcorp Plasma Focus™ liquid biopsy test now available (LabCorp Press Release)
"Labcorp...has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors. The test allows treating oncologists to evaluate circulating cell-free DNA (cfDNA) released by tumor cells and better manage the care of their patients through a personalized, targeted therapy plan."
Launch
|
Labcorp® Plasma Focus™
11ms
Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix Blood Test to Detect Prostate Cancer (Businesswire)
"Proteomedix...announced today that it entered into an agreement for Labcorp, a leading global life sciences company, to be the only laboratory to develop and commercialize the Proclarix® Prostate Specific Antigen (PSA) test in the U.S.. Proclarix is performed using the same blood sample as a PSA test, and is designed to help determine the risk of clinically significant prostate cancer for men with an elevated total PSA and a digital rectal examination that indicates elevated prostate volume, but who are not suspected of having cancer. In appropriate cases, the test provides a non-invasive alternative to a prostate biopsy, which can have significant side effects."
Licensing / partnership
|
Proclarix®
11ms
Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan (LabCorp Press Release)
"Labcorp...broke ground on a the expansion project of its CB Trial Laboratory in a ceremony held at the construction site near the BML Research Institute and General Laboratory in Kawagoe City on April 28, 2023...Labcorp will provide technological capabilities that will enable BML to significantly expand its specialty testing capabilities in the areas of genomics, anatomic pathology and histology, as well as the opportunity to partner on emerging companion diagnostics focused on oncology."
Licensing / partnership
11ms
Labcorp and Providence expand strategic laboratory relationship (LabCorp Press Release)
"Labcorp...announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations. Through the agreement, Labcorp will acquire Providence Oregon's outreach laboratory business and select assets in Oregon. Providence Oregon will maintain operation and ownership of certain anatomic pathology and genomics outreach testing and its hospital laboratories in the region."
M&A
12ms
Labcorp and Jefferson Health announce strategic laboratory relationship (LabCorp Press Release)
"Labcorp...announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson)...When complete, the arrangements between Jefferson and Labcorp will serve to build academic collaborations around teaching and the development of innovative tests...Jefferson and Labcorp will work together to establish the Innovation Driving Excellence in Academics (IDEA) initiative, with a goal of advancing testing capabilities and technologies to improve health outcomes."
Licensing / partnership
1year
Labcorp expands access to colorectal cancer screening through partnership with the Conference of National Black Churches (LabCorp Press Release)
"Labcorp...is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches will distribute over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond."
Licensing / partnership
1year
Labcorp, VieCure collaborate on NGS, software for cancer diagnosis (Genomeweb)
"Oncology bioinformatics startup VieCure said...that it will integrate its artificial intelligence-backed clinical decision support software with Laboratory Corporation of America's menu of next-generation sequencing tests for cancer diagnosis. Denver-based VieCure said that the strategic collaboration will lead to greater use of precision diagnostics and personalized treatment plans for patients in community health settings."
Licensing / partnership
over1year
Labcorp acquires clinical outreach laboratory services from RWJBarnabas Health (LabCorp Press Release)
"Labcorp...announced that it has closed its acquisition of RWJBarnabas Health’s outreach laboratory business and select related assets...Through this collaboration, RWJBarnabas Health’s physicians and patients will be able to access an expanded test menu, as well as Labcorp’s extensive network of patient service centers, which includes Labcorp at Walgreens."
Licensing / partnership
over1year
BD, Labcorp collaborate to develop flow cytometry-based companion diagnostics for matching patients with treatments (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced a collaboration agreement with Labcorp...creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases...The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry."
Licensing / partnership
almost2years
Labcorp forms strategic partnership with MD Anderson Cancer Center Foundation Spain to increase access to early phase oncology clinical trials (LabCorp Press Release)
"Labcorp...announced it has formed a strategic partnership with MD Anderson Cancer Center Foundation Spain, a non-profit organization whose objectives are to beat cancer and to increase accessibility of early phase oncology clinical trials. Through this collaboration, oncology clinical trials managed by Labcorp Drug Development will be prioritized and conducted at MD Anderson Cancer Center Foundation Spain, representing a new model for future trials."
Licensing / partnership
almost2years
Tigerlily Foundation and Labcorp collaborate to increase clinical trial diversity for women of color (LabCorp Press Release)
"Labcorp...announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life sciences companies in committing to eradicate barriers for women of color in accessing cancer care and research."
Clinical
almost2years
Labcorp expands access to comprehensive genomic testing through new lung cancer program (LabCorp Press Release)
"Labcorp...is announcing a new sponsored testing program aimed at helping advanced non-small cell lung (NSCLC) cancer patients and their physicians make informed treatment and care management decisions through comprehensive genomic insights...The program will use Labcorp’s OmniSeq INSIGHTSM test, a pan-cancer, tissue-based sequencing test, to provide comprehensive genomic and immune profiling for cases that meet eligibility criteria."
Clinical
|
OmniSeq INSIGHT
almost2years
Labcorp launches new test for people with skin cancer (LabCorp Press Release)
"Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp...The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue. LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. The test is available for use in both clinical trials and for the care and treatment of patients."
Launch
|
LAG-3 IHC assay
almost2years
Labcorp launches convenient home diagnostic test collection service in collaboration with Getlabs (LabCorp Press Release)
"Labcorp...announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp’s diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes...The samples can be used for Labcorp’s full range of testing, from standard wellness tests to advanced tests including liquid biopsies for cancer."
Licensing / partnership • Launch
2years
Labcorp completes acquisition of Personal Genome Diagnostics (LabCorp Press Release)
"Labcorp...announced that it has closed its acquisition of Personal Genome Diagnostics Inc...The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, positioning Labcorp at the forefront of driving better patient outcomes in oncology."
M&A
2years
PGDx announces an updated Medicare reimbursement rate for the elio™ tissue complete Test (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc...today announced an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio™ tissue complete. The Centers for Medicare & Medicaid Services (CMS) finalized a national reimbursement rate of $2,919.60 for the PLA code (0250U) that PGDx obtained for the test...The new Medicare payment rate went into effect on January 1, 2022."
Reimbursement
|
PGDx elio™ tissue complete assay
over2years
GenomOncology Pathology Workbench to Support OmniSeq INSIGHT, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors (PRNewswire)
"GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors....OmniSeq INSIGHT examines the full coding region of 523 genes by next generation sequencing for mutations, copy number alterations, fusions microsatellite instability (MSI), tumor mutation burden (TMB), and expression of 64 immune genes in the tumor microenvironment. The test also includes PD-L1 by immunohistochemistry."
Clinical
|
OmniSeq INSIGHT
over2years
Labcorp to acquire Personal Genome Diagnostics for up to $575M in cash (Genomeweb)
"Laboratory Corporation of America said Thursday that it has agreed to acquire cancer genomics firm Personal Genome Diagnostics (PGDx) for $450 million in cash and $125 million in additional payments based on future performance milestones...Labcorp added that it also plans to offer Baltimore-based PGDx's technology for use in clinical trials of cancer treatments."
M&A
over2years
Personal Genome Diagnostics and Cleveland Clinic Collaborate to Expand Utility of Liquid Biopsy Applications in Oncology Clinical Research (Personal Genome Diagnostics Press Release)
“Personal Genome Diagnostics…announced a collaboration with the Center for Immunotherapy and Precision Immuno-Oncology (CITI) and the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio. Both parties will collaborate to enhance capabilities within elioTM plasma complete reporting, as well as collaborate on the development of proprietary methods for complex biomarker detection and assay iterations to meet emerging liquid biopsy applications in solid tumors. This strategic collaboration combines Cleveland Clinic’s world-class research and commitment to innovation with the comprehensive PGDx portfolio and actionable genomic information. Both organizations are driven to elevate the standard of care for patients and increase utilization of precision diagnostics within the cancer care continuum.”
Licensing / partnership
|
PGDx elio™ plasma complete assay
over2years
New paper highlights capability of Personal Genome Diagnostics’ elio™ plasma resolve assay to detect microsatellite instability (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc...reported the publication of a research paper in The Oncologist, titled 'Validation of a ctDNA-based next-generation sequencing assay in a cohort of solid tumor patients: a proposed solution for decentralized plasma testing,' which assessed the performance of the company’s elio™ plasma resolve assay. This is the first study validating that a decentralized plasma-based next-generation sequencing (NGS) test can detect microsatellite instability (MSI) status along with the comprehensive landscape of sequence and structural alterations encountered across solid tumors."
Clinical data
|
PGDx elio™ plasma resolve assay
over2years
Tesis Labs and Personal Genome Diagnostics announce collaboration to advance cancer profiling and treatment (Personal Genome Diagnostics Press Release)
"Tesis Labs...and Personal Genome Diagnostics Inc...announced a new collaboration to maximize the power of genetic sequencing and bioinformatics. Through this collaboration, the companies intend to combine resources and expertise to create new genomics solutions that could combat cancer and improve outcomes for patients, and advance market access initiatives to accelerate adoption in the market."
Licensing / partnership
over2years
Labcorp expands oncology portfolio with OmniSeq® acquisition (OmniSeq Press Release)
"Labcorp announced it is expanding its oncology portfolio by acquiring OmniSeq...The transaction bolsters Labcorp’s growing portfolio of diagnostic tests and clinical trial opportunities for people with cancer and the oncologists who treat them...Through the acquisition of OmniSeq, Labcorp enhances its oncology test menu designed to leverage breakthrough science and insights from clinical and patient data to deliver targeted cancer solutions and improve patient outcomes."
M&A
almost3years
The access to comprehensive genomic profiling coalition welcomes two new Members - PGDx and Sema4 (Personal Genome Diagnostics Press Release)
"The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Personal Genome Diagnostics (PGDx)...and Sema4...to its coalition of diagnostics companies, laboratory service providers, and CGP industry stakeholders to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer." "
Licensing / partnership
almost3years
Personal Genome Diagnostics and Massachusetts General Hospital enter strategic collaboration to advance development of precision diagnostics (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc. (PGDx) today announced a strategic collaboration with Massachusetts General Hospital (MGH). The two organizations will work closely on the development of innovative solutions aimed at enabling seamless introduction of next-generation sequencing and genomic-based tumor profiling capabilities across a diverse set of clinical operations and laboratory settings...This collaboration will aid in our goal of ensuring this powerful technology is broadly accessible to patients across all types of healthcare settings."
Licensing / partnership
almost3years
Personal Genome Diagnostics Enters Collaborative Partnership with Clinical Molecular Diagnostics Laboratory of Major University Health System (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc...today announced a collaborative partnership with the Duke University Health System (DUHS) Clinical Molecular Diagnostics Laboratory. As part of the collaborative partnership, PGDx’s elio™ tissue complete will be the primary technology platform for the laboratory’s clinical oncology genomic testing initiatives. The laboratory will also collaborate with PGDx on the development of next-generation data integration solutions aimed at optimizing clinical usability of genomic data and insights across the cancer care continuum."
Licensing / partnership
|
PGDx elio™ tissue complete assay
almost3years
Personal Genome Diagnostics launches elio™ plasma complete, a kit enabling decentralized, comprehensive liquid biopsy analysis for oncology research applications (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc. (PGDx)...today announced the launch of elio™ (empowering local insight for oncology) plasma complete, a NGS kit solution for comprehensive blood-based genomic analysis. The elio™ plasma complete kit is intended to support research in areas like biomarker discovery, therapy selection, and monitoring, and is ideal for investigating genetic mutations and genomic signatures in multiple cancer types."
Launch
|
PGDx elio™ plasma complete assay
almost3years
OmniSeq receives New York State approval for cancer genomic, immune profiling test (OmniSeq Press Release)
"OmniSeq said on Tuesday that it has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program for its Insight cancer genomic and immune profiling test...With the approval, the test, which detects genomic variants, genomic signatures, and immune gene expression to inform cancer treatment decisions, will be available to patients in New York."
Regulatory
|
OmniSeq INSIGHT
3years
Personal Genome Diagnostics and Fox Chase Cancer Center announce partnership to broaden liquid biopsy applications in oncology clinical research (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc. (PGDx)…today announced a strategic collaboration with Fox Chase Cancer Center in Philadelphia for the PGDx elio™ plasma resolve liquid biopsy panel. The strategic collaboration combines the world-class Fox Chase research and clinical expertise in the community healthcare setting with PGDx leadership in the development of comprehensive genomic products that can be distributed and used in laboratories worldwide, wherever patients seek treatment for their cancer. Both organizations are driven by the overall goal of bringing the highest standards of care to patients in communities across the globe."
Licensing / partnership
|
PGDx elio™ plasma resolve assay
over3years
Personal Genome Diagnostics and QIAGEN collaborate to offer integrated genomic testing and interpretation support (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc. (PGDx)...announced today that it has entered into a collaboration with QIAGEN to provide comprehensive genomic profiling tests and clinical decision support to molecular labs. Under the non-exclusive agreement, PGDx will be responsible for the distribution of the PGDx elio™ oncology products and kitted solutions. Laboratories that purchase the PGDx elio products will have an option to receive from QIAGEN standardized reporting, driven by professional guidelines for streamlined case review and sign-out. In addition, laboratories will receive access to QIAGEN’s QCI Interpret One for rapid, evidence-based reporting for next-generation sequencing (NGS) oncology tests at scale."
Licensing / partnership
|
PGDx elio™ tissue complete assay
over3years
Personal Genome Diagnostics and Almac Diagnostic Services Enter Strategic Collaboration to Enhance Patient Care in Oncology (Businesswire)
"PGDx and Almac Diagnostic Services will focus on providing access to tumor profiling assays for both tissue and plasma samples, specifically, PGDx elio™ tissue complete and PGDx elio™ plasma resolve. This collaboration will combine Almac’s world-class genomics services and expertise in development and delivery of molecular diagnostics with PGDx’s leadership in cancer genomics to accelerate solutions that will deliver precision medicine to more patients."
Licensing / partnership
|
PGDx elio™ tissue complete assay
over3years
Genosity announces strategic software collaboration with PGDx to support distribution of PGDx elio™ tissue complete to laboratories (Businesswire)
"Genosity, Inc…announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx)…that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete, a comprehensive diagnostic kit for genomic profiling of cancer…As part of the agreement, Genosity will incorporate the PGDx elio™ tissue complete assay into its software platform and professional consulting services."
Licensing / partnership
|
PGDx elio™ tissue complete assay
over3years
Personal Genome Diagnostics Announces Medicare Coverage of PGDx elio tissue complete Assay for Patients with Advanced Cancer (Businesswire)
"Personal Genome Diagnostics Inc...announced...that the CMS Molecular Diagnostics Program (MolDX) has issued a local coverage determination (LCD) for the FDA-cleared PGDx elio™ tissue complete assay. The MolDX coverage determination establishes reimbursement for laboratory facilities across the 28-state MolDx jurisdiction, extending Medicare benefits for this comprehensive genomic test to patients living with advanced cancers."
Reimbursement
|
PGDx elio™ tissue complete assay